Evidence map›Paper›PMID 40277511›Full record

ArticleAdvances in respiratory medicine2025

Heterozygous

Max B Albers, Ludger Fink, Jerena Manoharan, Caroline L Lopez, Carmen Bollmann, Detlef K Bartsch

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in respiratory medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Max B AlbersDepartment of Visceral, Thoracic and Vascular Surgery, University Hospital of Giessen and Marburg, Philipps University of Marburg, 35043 Marburg, Germany.ORCID 0000-0002-1479-8557
Ludger FinkInstitute of Pathology, Dermatopathology, Cytology and Molecular Pathology, UEGP, 35578 Wetzlar, Germany.
Jerena ManoharanDepartment of Visceral, Thoracic and Vascular Surgery, University Hospital of Giessen and Marburg, Philipps University of Marburg, 35043 Marburg, Germany.ORCID 0000-0003-1611-2712
Caroline L LopezDepartment of Visceral, Thoracic and Vascular Surgery, University Hospital of Giessen and Marburg, Philipps University of Marburg, 35043 Marburg, Germany.
Carmen BollmannDepartment of Visceral, Thoracic and Vascular Surgery, University Hospital of Giessen and Marburg, Philipps University of Marburg, 35043 Marburg, Germany.
Detlef K BartschDepartment of Visceral, Thoracic and Vascular Surgery, University Hospital of Giessen and Marburg, Philipps University of Marburg, 35043 Marburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBronchopulmonary Neuroendocrine Neoplasms (NEN) occur in 2-7% of patients with multiple endocrine neoplasia type 1 (MEN1). Precursor lesions have been identified for MEN1-related pancreatic, duodenal, and gastric NEN. The aim of the current study using a MEN1 mouse model was to define the precursor lesions of bronchopulmonary NEN and evaluate the potential prophylactic antitumor effects of somatostatin analogues in a transgenic MEN1 mouse model.

methodsFifteen mice, germline heterozygous for

resultsIn the lungs of the 30 evaluated mice, whether treated or placebo treated, no bronchopulmonary neuroendocrine cell hyperplasia nor neuroendocrine neoplasia was detected through histopathology. However, pulmonary adenocarcinoma developed in 2 (13%) of the 15 untreated mice and in 1 (7%) of the 15 lanreotide-treated mice.

conclusionsHeterozygous

Indexed as

AdenocarcinomaBronchial NeoplasmsLung NeoplasmsMultiple Endocrine Neoplasia Type 1Neuroendocrine TumorsAdenocarcinoma of LungAnimalsDisease Models, AnimalHeterozygoteHyperplasiaMaleMiceMice, KnockoutPeptides, CyclicProto-Oncogene ProteinsSomatostatinlanreotideMen1 protein, mousePeptides, CyclicProto-Oncogene ProteinsSomatostatinbronchial adenocarcinomabronchial neuroendocrine neoplasiaMEN1multiple endocrine neoplasia

Identifiers

PMID40277511
PMCPMC12024158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.